Financial Performance - The company's operating revenue for the reporting period is expected to be CNY 166.21 million, a decrease of 22.73% year-on-year[5]. - The net profit attributable to shareholders is expected to be CNY 50.75 million, down 40.12% compared to the previous year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be CNY 43.53 million, a decrease of 48.10% year-on-year[5]. - The basic earnings per share is expected to be CNY 0.65, a decline of 53.90% compared to the same period last year[5]. Assets and Equity - Total assets at the end of the reporting period are expected to be CNY 703.22 million, an increase of 128.78% year-on-year[5]. - The equity attributable to shareholders is expected to be CNY 652.64 million, up 129.49% from the beginning of the period[5]. Market Conditions - The company's earnings decline is primarily due to intensified market competition and reduced demand from end customers for key products[5]. - The sales price of the main veterinary raw material, Sulfamethazine Sodium, has decreased due to increased market competition[5]. - The company plans to address the decline in sales volume of Crystalline Sulfamethazine and Dexamethasone products[5]. Financial Reporting - The financial data presented is preliminary and has not been audited, indicating potential discrepancies with the final report[6].
海昇药业(870656) - 2024 Q4 - 年度业绩